课题基金 / 基金详情

DIAGNOSIS OF ENTAMOEBA HISTOLYTICA INFECTION

DIAGNOSIS OF ENTAMOEBA HISTOLYTICA INFECTION
溶组织内阿米巴感染的诊断
批准号:
2072212
负责人:
David M. Lyerly
金额:
$6.36万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1994
资助国家:
美国
项目状态:
已结题
起止时间:
1994-09-01 至 1995-02-28

项目摘要

项目成果

David M. Lyerly的其他基金

相关文献

中文摘要
翻译
据信,溶组织内阿米巴感染了5亿人 每年一次。其中约10%的人出现症状并 发展为结肠炎和肝脓肿,死亡率超过 每年有4万人。目前的诊断方法是 粪便标本中有机体的显微可视化。然而, 这种方法需要丰富的经验,很繁琐,而且可能不会 准确,如果没有在收集样本的几分钟内进行。在……里面 此外,t不区分非致病菌株和致病菌株。 这是一个主要的缺点,因为非致病菌株不会引起 疾病和感染了非致病菌株的人不需要 使用抗阿米巴药物治疗,这些药物有一些刺激性的一面 效果。以下项目将评估单抗的使用 基于抗体的ELISA用于检测体内有机体的存在 粪便标本,并区分非致病菌株和致病菌株。 ELISA是基于使用结合 特别是生物体的半乳糖粘附素。该项目将 优化酶联免疫吸附试验作为诊断试验,并开始分析粪便 标本以及肝活检和血清标本的存在 溶组织埃希氏菌抗原。结果将与显微镜检查相关联。 结果和酵母菌分析,这是昂贵和繁琐的 是目前区分非致病性和致病性的唯一手段 菌株。酶联免疫吸附试验,将扩大到商业用途 应用程序,应作为诊断辅助工具使用,并将使 诊断更高效、更具成本效益。
英文摘要
Entamoeba histolytica is believed to infect a half billion people annually. Approximately 10% of these individuals become symptomatic and develop colitis and liver abscess with a mortality rate of more than 40,000 persons each year. The current methods of diagnosis is the microscopic visualization of the organism in fecal specimens. However, this method requires extensive experience, is tedious, and may not be accurate if not performed within minutes of collecting the specimen. In addition, t does not distinguish nonpathogenic and pathogenic strains. This is a major drawback because nonpathogenic strains do not cause disease and persons infected with nonpathogenic strains do not require treatment with antiamebic drugs, which have a number of harsh side effects. The following project will evaluate the use of monoclonal antibody-based ELISAs designed to detect the presence of the organism in fecal specimens and to distinguish nonpathogenic from pathogenic strains. The ELISAs are based on the use of monoclonal antibodies that bind specifically to the galactose adhesin of the organism. The project will optimize the ELISA as a diagnostic test and begin to analyze fecal specimens as well as liver biopsy and serum specimens for the presence of E.histolytica antigen. Results will be correlated with microscopy results and with zymodeme analysis, which is expensive and tedious and is the only current means of distinguishing nonpathogenic from pathogenic strains. The ELISA tests, which will be scaled up for commercial application, should be useful as diagnostic aids and will make the diagnosis more efficient and cost-effective.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Alum-absorbed subunit vaccine to prevent intestinal amebiasis
  • 批准号:
    8122722
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2011
  • 负责人:
    David M. Lyerly
  • 依托单位:
Alum-absorbed subunit vaccine to prevent intestinal amebiasis
  • 批准号:
    8303054
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2011
  • 负责人:
    David M. Lyerly
  • 依托单位:
New Diagnostics for Amebiasis
  • 批准号:
    6736678
  • 项目类别:
  • 资助金额:
    $49.85万
  • 财政年份:
    2004
  • 负责人:
    David M. Lyerly
  • 依托单位:
New Diagnostics for Amebiasis
  • 批准号:
    6895799
  • 项目类别:
  • 资助金额:
    $48.1万
  • 财政年份:
    2004
  • 负责人:
    David M. Lyerly
  • 依托单位: